Találati lista | Tudóstér

001-es BibID:	BIBFORM099465
Első szerző:	Jóna Ádám (orvos)
Cím:	Pulmonary Toxicity of Hodgkin Lymphoma Treatment : a Prospective Single-Center Study / Jona Adam, Miltenyi Zsofia, Pinczes Laszlo, Kerek Patricia, Bittner Nora, Szilasi Maria, Barna Sandor, Illes Arpad
Dátum:	2021
ISSN:	1927-1212 1927-1220
Megjegyzések:	Background: Standard bleomycin-containing first-line therapy and/or irradiation may cause pulmonary toxicity in Hodgkin lymphoma (HL) patients. Our aim was to prospectively assess effects of chest irradiation, bleomycin administration, and other factors on lung function in the treatment of patients with HL.Methods: Pulmonary function of newly diagnosed HL patients was assessed via a St. George Respiratory Questionnaire, dynamic inhalation lung scintigraphy, spirometry, and an assessment of the diffusion capacity of the lung for carbon monoxide (DLCO) before, during, and after treatment.Results: This prospective study was conducted at the University of Debrecen. The study included 84 patients with classical HL. Most patients received standard doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy. Both intramuscular and intravenous administrations of bleomycin were used. Brentuximab vedotin combination chemotherapy was administered to 12 patients. Mediastinal involved-field irradiation therapy (IFRT) was used to treat 16 patients. Lung scintigraphy revealed pulmonary toxicity more sensitively than DLCO. Intravenous bleomycin administration decreased diethylenetriamine pentaacetic acid clearance. Intramuscular bleomycin had the lowest level of pulmonary toxicity among considered treatments. Currently used, mediastinal IFRT had a lower level of pulmonary toxicity than bleomycin. The current prospec-tive evaluation confirmed previous results that determined that cumulative bleomycin dose and administration are major risk factors for pulmonary toxicity, while the currently used treatment method, mediastinal irradiation, was determined to be relatively safe for treating for HL patients.Conclusion: We agree with decreasing bleomycin dosage and number of cycles administered and we do not recommend avoiding mediastinal IFRT, unless multiple pulmonary risk factors are present.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Hodgkin lymphoma Pulmonary toxicity Bleomycin Irradiation Brentuximab vedotin Scintigraphy Pulmonary fibrosis Combination therapy
Megjelenés:	Journal of Hematology. - 10 : 6 (2021), p. 266-273. -
További szerzők:	Miltényi Zsófia (1975-) (belgyógyász, haematológus) Pinczés László Imre (1990-) (általános orvos) Kerek Patrícia (1996-) (Orvos) Bittner Nóra (1963-) (orvos) Szilasi Mária (1953-) (tüdőgyógyász, klinikai immunológus, allergológus, belgyógyász) Barna Sándor (1982-) (kutató orvos) Illés Árpád (1959-) (belgyógyász, haematológus, onkológus)
Pályázati támogatás:	UNKP-20-4 Egyéb
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM080564
035-os BibID:	(PMID)31228077
Első szerző:	Nyilas Renáta
Cím:	Interim PET/CT in diffuse large B-cell lymphoma may facilitate identification of good-prognosis patients among IPI-stratified patients / Renata Nyilas, Bence Farkas, Reka Rahel Bicsko, Ferenc Magyari, Laszlo Imre Pinczes, Arpad Illes, Lajos Gergely
Dátum:	2019
ISSN:	0925-5710 1865-3774
Megjegyzések:	Treating patients with DLBCL remains a challenge, as the response to first-line immunochemotherapy is somewhat unpredictable. The International Prognostic Index (IPI) is one of the most widely used methods for assessing prognosis. Interim PET/CT (iPET/CT) can play an important role in the early identification of 'non-responder' patients before the end of treatment examination. In this study, we retrospectively analyzed 104 newly diagnosed DLBCL patients treated with R-CHOP-like regimens who underwent iPET/CT imaging during therapy. There was a significant difference in 2-year OS between patients with negative iPET/CT and those with positive iPET/CT. Patients who had positive iPET/CT showed inferior 2-year PFS compared to those with negative iPET/CT. According to IPI, there was a statistically significant difference in 2-year OS and PFS between patients in the lower and higher risk groups. However, these patients can be further subdivided according to iPET/CT. The iPET/CT results in the present study clearly separate good- and poor-prognosis patients according to differences in 2-year OS, both in the lower and higher IPI risk groups. These results are in agreement with those of previous studies that demonstrated that iPET/CT has high negative predictive value, clearly identifying good-prognosis patients even within the poor-prognosis IPI group.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk DLBCL Diffuse large B-cell lymphoma Interim PET/CT PET/CT Response
Megjelenés:	International Journal of Hematology. - 110 : 3 (2019), p. 331-339. -
További szerzők:	Farkas Bence Bicskó Réka Ráhel (1994-) (általános orvos) Magyari Ferenc (1985-) (belgyógyász, hematológus) Pinczés László Imre (1990-) (általános orvos) Illés Árpád (1959-) (belgyógyász, haematológus, onkológus) Gergely Lajos (1965-) (belgyógyász, haematológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: